Cargando…

Safe administration of sotrovimab to a COVID-19 patient with acute phase type 1 diabetes mellitus

Type 1 diabetes mellitus (T1DM) and poor glycemic control are risk factors for severe coronavirus disease 2019 (COVID-19). Sotrovimab can treat mild-to-moderate COVID-19 in patients at a high risk of progression to severe COVID-19. However, its safety and efficacy in T1DM patients remain to be eluci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Haruna, Matsumoto, Masaaki, Hong, Sung Won, Mitsuboshi, Akari, Nagai, Masashi, Yoshino, Go, Otake, Shogo, Matsuo, Susumu, Yamada, Hiroyuki, Kurosawa, Hiroshi, Kasai, Masashi, Ozaki, Kayo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society for Pediatric Endocrinology 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068621/ https://www.ncbi.nlm.nih.gov/pubmed/37020700 http://dx.doi.org/10.1297/cpe.2022-0077

Ejemplares similares

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Dystrophin Dp116: A Yet to Be Investigated Product of the Duchenne Muscular Dystrophy Gene
por: Matsuo, Masafumi, et al.
Publicado: (2017)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
por: Zheng, Bang, et al.
Publicado: (2022)

Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
por: Mambelli, Emanuele, et al.
Publicado: (2022)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Treatment optimization by monitoring vancomycin concentration in the serum and cerebrospinal fluid in a child with cystoperitoneal shunt-related infection caused by methicillin-resistant Staphylococcus aureus: a case report and literature review
por: Mizuno, Shinsuke, et al.
Publicado: (2023)

Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series
por: Takeda, Kenichiro, et al.
Publicado: (2022)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

ODP484 Hyperthyroidism During Prostaglandin I2 Treatment in Pulmonary Hypertension and Its Molecular Mechanism
por: Ishida, Emi, et al.
Publicado: (2022)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Lack of efficacy for sotrovimab use in patients with COVID-19: A meta-analysis
por: Ao, Guangyu, et al.
Publicado: (2022)

Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection
por: Weber, Sven C., et al.
Publicado: (2022)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
por: Yoshida, Junichi, et al.
Publicado: (2022)

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US
por: Cheng, Mindy M, et al.
Publicado: (2022)

Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
por: Rasmussen, Line Dahlerup, et al.
Publicado: (2023)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases
por: Zheng, Bang, et al.
Publicado: (2023)

Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
por: Rockett, Rebecca, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Pulmonary arterial enlargement predicts cardiopulmonary complications after pulmonary resection for lung cancer: a retrospective cohort study
por: Asakura, Keisuke, et al.
Publicado: (2015)

Cardiac Dysfunction in Duchenne Muscular Dystrophy Is Less Frequent in Patients With Mutations in the Dystrophin Dp116 Coding Region Than in Other Regions
por: Yamamoto, Tetsushi, et al.
Publicado: (2018)

Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study
por: Elesdoudy, Ahmed
Publicado: (2021)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Mixed acinar-neuroendocrine carcinoma of the pancreas with positive for microsatellite instability: a case report and review of the literature
por: Yoshino, Kenji, et al.
Publicado: (2023)

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
por: Mader, Anna-Lena, et al.
Publicado: (2022)

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
por: Magnus, Clara Luzia, et al.
Publicado: (2022)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

An Evaluation Method for the Suppression of Pathogenic Fusarium oxysporum by Soil Microorganisms Using the Dilution Plate Technique
por: Mitsuboshi, Masahiro, et al.
Publicado: (2016)

Evaluation of Suppressiveness of Soils Exhibiting Soil-Borne Disease Suppression after Long-Term Application of Organic Amendments by the Co-cultivation Method of Pathogenic Fusarium oxysporum and Indigenous Soil Microorganisms
por: Mitsuboshi, Masahiro, et al.
Publicado: (2018)

An Evaluation Method for Suppression of Pathogenic Fusarium oxysporum by Soil Microorganisms Using the Dilution Plate Technique
por: Mitsuboshi, Masahiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oeila82elke3db7rk0j6uk9uqq